Found: 8
Select item for more details and to access through your institution.
Blockade of Cholecystokinin Type 2 Receptors Prevents the Onset of Vincristine-Induced Neuropathy in Mice.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 12, p. 2823, doi. 10.3390/pharmaceutics14122823
- By:
- Publication type:
- Article
Neuroprotective Effect of Ramipril Is Mediated by AT2 in a Mouse MODEL of Paclitaxel-Induced Peripheral Neuropathy.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 4, p. N.PAG, doi. 10.3390/pharmaceutics14040848
- By:
- Publication type:
- Article
Netazepide, an Antagonist of Cholecystokinin Type 2 Receptor, Prevents Vincristine-Induced Sensory Neuropathy in Mice.
- Published in:
- Pharmaceuticals (14248247), 2024, v. 17, n. 2, p. 144, doi. 10.3390/ph17020144
- By:
- Publication type:
- Article
The Cholecystokinin Type 2 Receptor, a Pharmacological Target for Pain Management.
- Published in:
- Pharmaceuticals (14248247), 2021, v. 14, n. 11, p. 1185, doi. 10.3390/ph14111185
- By:
- Publication type:
- Article
The Angiotensin II Type 2 Receptor, a Target for Protection and Regeneration of the Peripheral Nervous System?
- Published in:
- Pharmaceuticals (14248247), 2021, v. 14, n. 3, p. 175, doi. 10.3390/ph14030175
- By:
- Publication type:
- Article
Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways.
- Published in:
- EMBO Molecular Medicine, 2017, v. 9, n. 12, p. 1681, doi. 10.15252/emmm.201707729
- By:
- Publication type:
- Article
Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice.
- Published in:
- Frontiers in Pharmacology, 2021, v. 12, p. 1, doi. 10.3389/fphar.2021.712442
- By:
- Publication type:
- Article
The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status.
- Published in:
- Neuro-Oncology, 2013, v. 15, n. 9, p. 1200, doi. 10.1093/neuonc/not054
- By:
- Publication type:
- Article